Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003322 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 384
- Enrollment target
NCT00003322 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 384 participants.
The verdict
NCT00003322, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 384 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether intravenous two-drug combination chemotherapy is more effective than intravenous and intraperitoneal infusions of three-drug combination chemotherapy for treating primary peritoneal or stage III epithelial ovarian cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intravenous two-drug combination chemotherapy with intravenous and intraperitoneal three-drug combination chemotherapy in treating patients who have primary peritoneal or stage III epithelial ovarian cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE quality-of-life assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 1998-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003322
The ClinicalTrials.gov registry entry for NCT00003322 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003322 about?
NCT00003322 is a clinical study titled "Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether intravenous two-drug combination chemotherapy is more effecti...
What is the current status of trial NCT00003322?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 384 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00003322?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), quality-of-life assessment (PROCEDURE).
Who is sponsoring clinical trial NCT00003322?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.